We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Par Sues UCB Over Generic Keppra

Law360 (March 25, 2011, 2:04 PM EDT) -- Par Pharmaceutical Cos. Inc. filed suit Wednesday in Pennsylvania seeking declaratory judgment that its proposed generic version of epilepsy treatment Keppra XR doesn't infringe UCB Pharma SA's patents covering the drug.

Par's submission of an abbreviated new drug application for permission to manufacture generic oral levetiracetam extended release tablets does not infringe U.S. Patent Numbers 7,858,122 and 7,863,316 because the patents are invalid and unenforceable, the plaintiff claims in a complaint filed in the U.S. District Court for the Eastern District of Pennsylvania.

The asserted patents,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.